Skip to main content
G2GBIO, Inc. logo

G2GBIO, Inc. — Investor Relations & Filings

Ticker · 456160 ISIN · KR7456160001 KO Manufacturing
Open in API
Filings indexed 89 across all filing types
Latest filing 2025-07-30 Capital/Financing Update
Country KR South Korea
Listing KO 456160

About G2GBIO, Inc.

https://www.g2gbio.com/

G2GBIO, Inc. is a biotechnology company specializing in sustained-release pharmaceuticals through its proprietary drug delivery system platform. The company's core technology, InnoLAMP (Innovative Long-Acting MicroParticle), is used to develop long-acting injectable microspheres that provide a controlled, extended release of therapeutic agents. This platform aims to improve treatment efficacy and patient compliance for chronic diseases by reducing dosing frequency. G2GBIO's research and development pipeline is focused on creating long-acting formulations for conditions including Alzheimer's disease, Type 2 diabetes, schizophrenia, and post-operative pain. The company also develops specialized applications for targeted drug delivery in areas such as oncology.

Recent filings

Filing Released Lang Actions
투자설명서
Capital/Financing Update Classification · 98% confidence The document is a '투자설명서' (Investment Prospectus) for G2G Bio Co., Ltd., dated July 30, 2025. It details the public offering of 900,000 shares, including offering price ranges, subscription periods, and detailed risk factors (business and company risks). In the context of financial filings, a prospectus for an IPO or public offering is classified as a Proxy Solicitation & Information Statement (PSI) or a regulatory filing related to capital raising. Given the specific categories provided, 'PSI' (Proxy Solicitation & Information Statement) is the most appropriate fit for a formal investment prospectus document used to solicit investor interest and provide required disclosures.
2025-07-30 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed by G2G Bio (주)지투지바이오. It details amendments (정정신고) to a previously filed registration statement, including updates to underwriting fees, business risk disclosures, and patent strategy information. In the context of financial filings, a Securities Registration Statement is a regulatory document required for public offerings, which falls under the 'Regulatory Filings' category as it does not fit into the specific categories like 10-K, ER, or IR.
2025-07-24 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Capital Increase Decision' (유상증자결정) for G2G Bio. It details the amendment of dates for a paid-in capital increase (rights offering/public offering), including subscription dates, payment dates, and listing dates. This falls under the category of share issuance and capital changes.
2025-07-08 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 98% confidence The document is a 'Correction Report' (정정신고서) for a Securities Registration Statement (증권신고서) filed by G2GBio. It details specific amendments to the initial registration statement, such as changes to the public offering schedule, subscription dates, and related financial terms. In the context of Korean financial regulations (DART system), a 'Correction Report' for a Securities Registration Statement is a formal regulatory filing that updates the terms of an ongoing IPO or capital raise. It does not fit into categories like 'Annual Report' or 'Earnings Release', and since it is a substantive amendment to a registration statement rather than a simple announcement of a report's availability, it is classified as a Regulatory Filing.
2025-07-08 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission (금융위원회) regarding a decision for a paid-in capital increase (유상증자결정). It details the issuance of new shares, the purpose of funds, and the offering method. This falls under the category of share issuance and capital changes.
2025-06-17 Korean
증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed by G2GBio (주식회사 지투지바이오) with the Financial Services Commission (금융위원회) in South Korea. It details the company's intent to offer shares, provides comprehensive investment risk factors, business descriptions, and financial projections. This is a formal regulatory filing required for an IPO or public offering of securities, which falls under the 'Regulatory Filings' category as it is a primary legal document for public offering registration.
2025-06-17 Korean

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.